Literature DB >> 16698276

Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan.

Kazunori Kusumoto1, Hirofumi Uto, Katsuhiro Hayashi, Yuka Takahama, Hiroyuki Nakao, Robert Suruki, Sherri O Stuver, Akio Ido, Hirohito Tsubouchi.   

Abstract

We investigated the effects of polymorphisms in interleukin (IL)-10 and tumor necrosis factor (TNF)-alpha on the natural course of hepatitis C virus (HCV) infection in a community-based population in Japan. A total of 460 anti-HCV antibody seropositive individuals were classified into two groups, those who were positive or negative for HCV RNA. In HCV RNA-positive individuals with at least four annual alanine aminotransferase (ALT) measurements taken between 1993 and 2003, 74 exhibited persistently normal ALT levels, while 211 had one or more elevated ALT level tests. We examined the relationships between polymorphisms in the genes encoding IL-10 (-1082, -819, -592) or TNF-alpha (-308, -238) and HCV clearance, ALT abnormalities, or serum level of type IV collagen 7S, a marker of hepatic fibrosis. These polymorphisms were equally distributed among the patient subgroups with differential HCV RNA clearances or ALT abnormalities. Serum levels of type IV collagen 7S, however, were significantly higher in individuals with an A at position -238 or -308 in the TNF-alpha gene promoter than in individuals lacking these polymorphisms. We conclude that, while the relationships between inherited variations in IL-10 or TNF-alpha expression are not associated with alterations in HCV clearance or ALT levels, TNF-alpha polymorphisms may be associated with hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698276     DOI: 10.1016/j.cyto.2006.03.011

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  19 in total

1.  Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case control study.

Authors:  Samaneh Sepahi; Alireza Pasdar; Mitra Ahadi; Sina Gerayli; Sina Rostami; Zahra Meshkat
Journal:  Viral Immunol       Date:  2014-08-13       Impact factor: 2.257

Review 2.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 3.  Host genetic factors and antiviral immune responses to hepatitis C virus.

Authors:  Chloe L Thio
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

4.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

5.  Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.

Authors:  Yuka Takahama; Hirofumi Uto; Shuji Kanmura; Makoto Oketani; Akio Ido; Kazunori Kusumoto; Satoru Hasuike; Kenji Nagata; Katsuhiro Hayashi; Sherri Stuver; Akihiko Okayama; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

6.  IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India.

Authors:  Roli Saxena; Yogesh Kumar Chawla; Indu Verma; Jyotdeep Kaur
Journal:  Mol Cell Biochem       Date:  2013-10-08       Impact factor: 3.396

7.  Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.

Authors:  Hirofumi Uto; Sherri O Stuver; Katsuhiro Hayashi; Kotaro Kumagai; Fumisato Sasaki; Shuji Kanmura; Masatsugu Numata; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Akio Ido; Kazunori Kusumoto; Satoru Hasuike; Kenji Nagata; Michinori Kohara; Hirohito Tsubouchi
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

8.  Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.

Authors:  Amy Thomas; Carl Laxton; Joanne Rodman; Nisha Myangar; Nigel Horscroft; Tanya Parkinson
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

9.  Role of host genetic factors in the outcome of hepatitis C virus infection.

Authors:  Bertram Bengsch; Robert Thimme; Hubert E Blum
Journal:  Viruses       Date:  2009-08-05       Impact factor: 5.818

10.  Role of host genetics in fibrosis.

Authors:  Georgina L Hold; Paraskevi Untiveros; Karin A Saunders; Emad M El-Omar
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.